Compare AbCellera Biologics Inc (ABCL) vs Expedia Group Inc (EXPE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Expedia Group Inc — how do they compare? AbCellera Biologics Inc trades at $7.1 (market cap $2.35B), while Expedia Group Inc trades at $260.31 (market cap $32.39B). The key difference: Expedia Group Inc is far larger — about 13.8× AbCellera Biologics Inc's market cap, and Expedia Group Inc pays a 0.65% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | EXPE | |
|---|---|---|
Market Cap | $2.35B | $32.39B |
Sector | Health | Consumer Cyclical |
52-Week High | $8.12 | $301.31 |
52-Week Low | $2.78 | $176.09 |
Enterprise Value | $1.99B | $31.30B |
Dividend Yield | — | 0.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Expedia Group (EXPE) trades at $269.87, up 0.44% with a bullish technical outlook supported by moving averages and strong fundamental performance. The company reported consistent earnings beats in recent quarters with Q1 2026 EPS of $1.96 exceeding expectations of $1.41. Revenue growth has been steady, climbing from $11.7B in 2022 to $14.7B in 2025, while maintaining robust profitability with a 90.27% gross margin. Recent developments include the CarTrawler acquisition and positive travel industry research positioning the company for continued growth.
EXPE presents a compelling investment case with analyst consensus price target of $281.75 representing 4.4% upside potential. The stock offers exposure to the resilient travel sector with improving operational efficiency and strong cash flow generation. Key risks include travel sector volatility and competitive pressures, but the company's technological innovation and market position provide defensive characteristics in the evolving travel landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →
